Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 2024
July 17, 2019 00:14 ET | Repligen Corporation
WALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurrent underwritten public offerings of 1,380,000 shares of its...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes
July 15, 2019 16:02 ET | Repligen Corporation
WALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced concurrent underwritten public offerings of $100,000,000 in...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Present at Jefferies 2019 Healthcare Conference
June 04, 2019 10:03 ET | Repligen Corporation
WALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres,...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
May 09, 2019 07:30 ET | Repligen Corporation
Reports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growthRaises revenue guidance to $235-$241 million for full year 2019, representing 22%-25%...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report First Quarter 2019 Financial Results
May 02, 2019 14:20 ET | Repligen Corporation
WALTHAM, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019 financial results on Thursday, May 9, 2019....
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation Prices Public Offering of Shares of Common Stock
April 30, 2019 19:36 ET | Repligen Corporation
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
April 29, 2019 16:19 ET | Repligen Corporation
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results
April 26, 2019 07:30 ET | Repligen Corporation
Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessingAdds a market leader in protein concentration measurement with...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen Reports Fourth Quarter and Full Year 2018 Financial Results
February 21, 2019 07:30 ET | Repligen Corporation
Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growthOverall organic revenue growth was 25%...
Repligen_Logo-HORIZONTAL-withtagline (1).jpg
Repligen to Report Fourth Quarter and Full Year 2018 Financial Results
February 15, 2019 07:30 ET | Repligen Corporation
WALTHAM, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on Thursday,...